Compare Suven Life Sciences with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE SCIENCES vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE SCIENCES DIVIS LABORATORIES SUVEN LIFE SCIENCES/
DIVIS LABORATORIES
 
P/E (TTM) x -83.4 54.2 - View Chart
P/BV x 1.3 14.5 9.0% View Chart
Dividend Yield % 1.8 0.4 416.5%  

Financials

 SUVEN LIFE SCIENCES   DIVIS LABORATORIES
EQUITY SHARE DATA
    SUVEN LIFE SCIENCES
Mar-19
DIVIS LABORATORIES
Mar-19
SUVEN LIFE SCIENCES/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3381,639 20.6%   
Low Rs1691,115 15.2%   
Sales per share (Unadj.) Rs52.1186.3 28.0%  
Earnings per share (Unadj.) Rs6.851.0 13.4%  
Cash flow per share (Unadj.) Rs8.657.3 15.0%  
Dividends per share (Unadj.) Rs1.5016.00 9.4%  
Dividend yield (eoy) %0.61.2 50.9%  
Book value per share (Unadj.) Rs65.3261.8 24.9%  
Shares outstanding (eoy) m127.28265.47 47.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.97.4 65.8%   
Avg P/E ratio x37.127.0 137.3%  
P/CF ratio (eoy) x29.624.0 123.1%  
Price / Book Value ratio x3.95.3 73.8%  
Dividend payout %22.031.4 69.9%   
Avg Mkt Cap Rs m32,272365,592 8.8%   
No. of employees `0001.111.8 9.1%   
Total wages/salary Rs m6615,423 12.2%   
Avg. sales/employee Rs Th6,132.24,175.1 146.9%   
Avg. wages/employee Rs Th611.1457.7 133.5%   
Avg. net profit/employee Rs Th803.51,141.8 70.4%   
INCOME DATA
Net Sales Rs m6,63549,463 13.4%  
Other income Rs m2421,556 15.6%   
Total revenues Rs m6,87751,019 13.5%   
Gross profit Rs m1,60418,718 8.6%  
Depreciation Rs m2211,689 13.1%   
Interest Rs m3835 107.7%   
Profit before tax Rs m1,58718,551 8.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7185,023 14.3%   
Profit after tax Rs m86913,527 6.4%  
Gross profit margin %24.237.8 63.9%  
Effective tax rate %45.227.1 167.0%   
Net profit margin %13.127.3 47.9%  
BALANCE SHEET DATA
Current assets Rs m6,23246,501 13.4%   
Current liabilities Rs m1,4908,468 17.6%   
Net working cap to sales %71.576.9 92.9%  
Current ratio x4.25.5 76.2%  
Inventory Days Days86131 66.1%  
Debtors Days Days8386 96.2%  
Net fixed assets Rs m4,04325,797 15.7%   
Share capital Rs m127531 24.0%   
"Free" reserves Rs m8,18368,962 11.9%   
Net worth Rs m8,31069,493 12.0%   
Long term debt Rs m180-   
Total assets Rs m10,38980,383 12.9%  
Interest coverage x43.1531.0 8.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.6 103.8%   
Return on assets %8.716.9 51.8%  
Return on equity %10.519.5 53.7%  
Return on capital %19.526.7 73.0%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m5,62241,238 13.6%   
Fx outflow Rs m1,79912,405 14.5%   
Net fx Rs m3,82228,833 13.3%   
CASH FLOW
From Operations Rs m3569,543 3.7%  
From Investments Rs m-279-6,854 4.1%  
From Financial Activity Rs m-225-2,459 9.2%  
Net Cashflow Rs m-148230 -64.5%  

Share Holding

Indian Promoters % 63.4 52.0 121.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 11.8 -  
FIIs % 0.0 19.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 17.2 212.2%  
Shareholders   37,287 31,796 117.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE SCIENCES With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare SUVEN LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

6 Reasons Why Sensex Plunged 883 Points Today(Closing)

Indian share markets nosedived and registered sharp losses in today's volatile session following a strong second wave of Covid-19 in the country.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SCIENCES SHARE PRICE


Apr 19, 2021 03:36 PM

TRACK SUVEN LIFE SCIENCES

  • Track your investment in SUVEN LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFE SCIENCES

SUVEN LIFE SCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFE SCIENCES WITH

MARKET STATS